Sato Pharmaceutical Initiates Class II Recall of INON ACE Antacid Tablets Over Disintegration Failures
Sato Pharmaceutical Co., Ltd. has initiated a Class II voluntary recall (D-0298-2026) for 3,640 bottles of INON ACE Antacid tablets in CA and HI. The recall stems from the product failing disintegration specifications, taking longer than expected to dissolve. This event underscores the critical need for robust quality control in OTC drug manufacturing, impacting supply chain reliability for magnesium-based antacids.
FDA-Initiated Class II Recall: Sato Pharmaceutical's INON ACE Antacid Disintegration Failure
Sato Pharmaceutical Co., Ltd., a Tokyo, Japan-based manufacturer, has initiated a voluntary Class II recall, identified as D-0298-2026, for its INON ACE Antacid tablets. This action, commenced on December 19, 2025, addresses a critical quality deficiency: the product failed disintegration specifications, meaning the tablets took longer than expected to break down in the body. The specific lot affected is PWXT, with an expiration date of January 31, 2027. This recall impacts 3,640 bottles of the 75-count product (NDC 49873-402-01), which were distributed across California (CA) and Hawaii (HI). For procurement directors and supply chain VPs, this event highlights the immediate need to assess inventory levels and potential disruptions for antacid products containing magnesium aluminosilicates, magnesium hydroxide, and simethicone. The failure of a tablet to disintegrate properly can compromise its therapeutic efficacy, directly impacting patient outcomes and posing a significant regulatory risk. Businesses relying on Sato Pharmaceutical for similar over-the-counter (OTC) formulations must immediately review their quality assurance protocols and contingency plans to prevent supply chain vulnerabilities.
Manufacturing Oversight: Implications for Global OTC Drug Supply from Japan
The recall of INON ACE Antacid tablets underscores the critical importance of robust quality control within manufacturing facilities, even for established global players like Sato Pharmaceutical Co., Ltd. While specific facility details, such as an FDA FEI number or production capacity, are not disclosed in the current regulatory filing, the fact that the manufacturing originates from Tokyo, Japan, indicates a global reach for their products. For regulatory affairs heads, this incident signals that geographical distance does not diminish the FDA's scrutiny of product quality for drugs distributed within the U.S. market. The failure in disintegration specifications points to potential issues in formulation, manufacturing processes, or raw material quality control. Companies sourcing finished products or active pharmaceutical ingredients (APIs) from Japanese manufacturers, particularly for high-volume OTC drugs like antacids, must ensure their supplier qualification processes include rigorous audits of quality management systems, process validation, and ongoing stability monitoring. This proactive approach is essential to mitigate the risk of similar quality deviations impacting their own product lines and market access.
Supply Chain Exposure: Managing Disruption for Magnesium-Based Antacids in US Markets
The distribution of 3,640 bottles of INON ACE Antacid tablets across California and Hawaii means that distributors, pharmacies, and retailers in these states are directly impacted by this Class II recall. For supply chain VPs and business development executives, this event necessitates an immediate assessment of inventory and sales channels for this specific product and potentially other antacid formulations from Sato Pharmaceutical. A Class II classification indicates that the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. While not life-threatening, a failed disintegration can lead to ineffective treatment for consumers, eroding brand trust and potentially leading to returns or complaints. Procurement teams should identify alternative sources for antacid products containing magnesium aluminosilicates, magnesium hydroxide, and simethicone to prevent stock-outs and ensure continuity of supply. This incident highlights the fragility of relying on a single supplier or a limited supply chain for essential OTC medications, emphasizing the need for robust supplier diversification strategies and real-time inventory management across all distribution points.
Mitigating Risk: Diversifying Sourcing for Key Antacid Ingredients
Given the recall of INON ACE Antacid tablets due to disintegration issues, procurement directors must critically evaluate their sourcing strategies for key active pharmaceutical ingredients (APIs) such as magnesium aluminosilicates, magnesium hydroxide, and simethicone. While specific alternative suppliers for Sato Pharmaceutical are not identified in the available intelligence, the market for these common antacid components is diverse. Companies should proactively identify and qualify multiple suppliers across different geographical regions to build resilience into their supply chains. For instance, reputable manufacturers of magnesium-based APIs can be found in regions beyond Japan, including India, China, and parts of Europe. The qualification process should not only focus on price and capacity but also on a supplier's regulatory compliance history, quality control processes, and ability to provide comprehensive Certificates of Analysis (CoAs) that include dissolution or disintegration testing data. Establishing secondary and tertiary qualified suppliers is a strategic imperative to prevent disruptions and ensure product quality, especially for high-volume OTC products where even minor quality deviations can trigger costly recalls and reputational damage.
Broader Regulatory Landscape: Persistent Quality Challenges in OTC Drug Manufacturing
The Class II recall of Sato Pharmaceutical's INON ACE Antacid tablets is not an isolated incident but reflects a broader trend of quality control challenges within the global pharmaceutical industry, particularly for over-the-counter (OTC) medications. Recent parallel events highlight this persistent vulnerability. For example, Essential Wellness Pharma faced a Class II recall for Progesterone Injection due to sterility assurance failures in June 2026, and Spectra Medical Devices initiated a high-severity Class II recall for Lidocaine HCl Injection for similar sterility deficiencies. Furthermore, Guardian Drug Co. Inc. executed a nationwide recall for metallic contamination in Calcium Carbonate Antacids in June 2026. These incidents, alongside Sato Pharmaceutical's disintegration failure, underscore that issues ranging from microbial contamination to physical defects and foreign matter are recurring regulatory concerns. Regulatory affairs heads must recognize that the FDA maintains a vigilant stance on manufacturing quality, irrespective of product classification or therapeutic area. This pattern necessitates that all pharmaceutical companies, particularly those involved in OTC drug manufacturing, continuously review and enhance their Good Manufacturing Practices (GMP) to avoid costly recalls and maintain consumer trust.
Remediation Timeline and Future Compliance Outlook for Sato Pharmaceutical
As the Class II recall (D-0298-2026) for INON ACE Antacid tablets remains 'Ongoing,' Sato Pharmaceutical Co., Ltd. is under regulatory obligation to thoroughly investigate the root cause of the failed disintegration specifications and implement comprehensive corrective and preventive actions (CAPAs). For regulatory affairs heads, understanding this process is crucial. The FDA expects a detailed response outlining how the issue occurred, what steps are being taken to prevent recurrence, and how affected product has been managed. This typically involves re-evaluating raw material specifications, optimizing manufacturing parameters, and enhancing in-process and finished product testing. Failure to adequately address these deficiencies could lead to further FDA scrutiny, including potential import alerts for products manufactured at the Tokyo facility if distributed to the U.S. market, or even a Warning Letter. Business development executives should monitor Sato Pharmaceutical's remediation progress closely, as prolonged compliance issues can impact market access and partnership opportunities. Proactive engagement with regulatory bodies and transparent communication regarding corrective actions are paramount for restoring confidence and ensuring long-term market viability.